Fig. 3
From: COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm
Inhibition of SREBP-2 and NF-κB prevents the inflammatory cytokines and mRNA levels related to SREBP-2. a Activation level of SREBP-2 in COVID-19 ICU patients’s PBMCs by the treatment of NF-κB inhibitor (SN50) and SREBP-2 inhibitor (Fatostatin A) (**p < 0.01). b, c Level of IL-1β (b) and TNF-α (c) in COVID-19 ICU patients’s PBMCs by the treatment of SN50 and Fatostatin A (**p < 0.01). d–i Changed level of mRNA after the treatment of SN50 and Fatostatin A. d SREBF2, e IL-1β, f TNF-α, g SCAP, h INSIG1, and i SIRT1 (**p < 0.01)
